文献速递血栓与止血

直接口服抗凝药剂量选择:挑战性病例

Direct oral anticoagulant dose selection: Challenging cases.
PubMed 文献 · J Thromb Haemost · 2021-09-28

直接口服抗凝药(DOAC)按固定剂量给药且无需常规监测,但部分患者最佳剂量不确定,如房颤出血高风险但不符合减量标准者、静脉血栓栓塞完成3-6个月抗凝后需延长治疗者。本文以病例为基础综述这两类情境下的DOAC剂量选择。

要点

  • DOAC剂量选择应遵循关键III期试验的给药方式,但部分患者最佳剂量仍不确定。
  • 房颤出血高风险但不符合指南减量标准者,DOAC剂量选择存在挑战。
  • 静脉血栓栓塞完成3-6个月抗凝后延长治疗时,标准剂量或减量DOAC的选择需个体化。

核心结论

  • 对于房颤出血高风险但不符合指南减量标准者,以及静脉血栓栓塞完成3-6个月抗凝后需延长治疗者,DOAC最佳剂量仍不确定,需病例化决策。

研究设计与样本

  • 综述,采用基于病例的方法讨论两类临床情境下的DOAC剂量选择。

主要发现

  • 关键III期试验中,部分试验随机分配患者接受高剂量或低剂量DOAC,另一些试验多数患者接受标准剂量,仅对药物蓄积风险亚组给予低剂量。
  • 治疗指南推荐按试验测试方式确定DOAC剂量,但部分患者最佳剂量仍不确定。

临床怎么用

  • 房颤患者出血风险高但不符合指南减量标准时,需基于病例讨论DOAC剂量选择。
  • 静脉血栓栓塞完成3-6个月抗凝后延长治疗时,标准剂量或减量DOAC的选择需病例化评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Direct oral anticoagulants (DOACs) are given in fixed doses without routine laboratory monitoring of their anticoagulant effect based on the results of pivotal phase III trials. In some of these trials, patients were randomly allocated to receive a higher or lower dose of a DOAC, whereas in others, most patients were given a standard dose and only a subset deemed to be at risk of drug accumulation was given a lower dose. Treatment guidelines recommend dosing DOACs according to the way that they were tested in the trials, but for some patients, the optimal dosing remains uncertain. One example is patients with atrial fibrillation who are thought to have an unacceptably high risk of bleeding but do not meet the guideline criteria for dose reduction. A second is patients with venous thromboembolism who have completed 3 to 6 months of anticoagulation and are eligible for extended treatment with a standard or reduced dose of DOAC. In this review, we present a case-based approach to DOAC dose selection in these two settings.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Carlin S, Eikelboom JW. Direct oral anticoagulant dose selection: Challenging cases. J Thromb Haemost. 2021. PMID: 34558172. doi:10.1111/jth.15536

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。